EMERGENT BIOSOLUTIONS INC. Gain (Loss) on Disposition of Business
EMERGENT BIOSOLUTIONS INC. (EBS) reported Gain (Loss) on Disposition of Business of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnSaleOfBusiness · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of business for the quarter ending 2025-12-31 was $12.20M.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of business for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of business for the quarter ending 2024-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of business for the quarter ending 2024-09-30 was $64.30M.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of business for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of business for fiscal 2024 was $24.30M, a 67.25% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of business for fiscal 2023 was $74.20M.
- EMERGENT BIOSOLUTIONS INC. gain (loss) on disposition of business for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Disposition of Business 3 month | Gain (Loss) on Disposition of Business 6 month | Gain (Loss) on Disposition of Business 9 month | Gain (Loss) on Disposition of Business 12 month |
|---|---|---|---|---|
| 2025-12-31 | $12.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $12.20M derived: sum of 2 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 | -$12.20M 10-Q · filed 2025-10-30 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $64.30M derived: sum of 2 quarters · filed 2026-02-27 | $24.30M derived: sum of 3 quarters · filed 2026-02-27 | $24.30M 10-K · filed 2026-02-27 |
| 2024-09-30 | $64.30M 10-Q · filed 2025-10-30 | $24.30M derived: sum of 2 quarters · filed 2025-10-30 | $24.30M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | -$40.00M 10-Q · filed 2024-08-07 | -$40.00M 10-Q · filed 2024-08-07 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$700.00K derived: sum of 2 quarters · filed 2026-02-27 | $74.20M derived: sum of 3 quarters · filed 2026-02-27 | $74.20M 10-K · filed 2026-02-27 |
| 2023-09-30 | -$700.00K 10-Q · filed 2024-11-07 | $74.20M derived: sum of 2 quarters · filed 2024-11-07 | $74.20M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $74.90M 10-Q · filed 2024-08-07 | $74.90M 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $0.00 derived: sum of 2 quarters · filed 2025-03-04 | $0.00 derived: sum of 3 quarters · filed 2025-03-04 | $0.00 10-K · filed 2025-03-04 |
| 2022-09-30 | $0.00 10-Q · filed 2023-12-11 | $0.00 derived: sum of 2 quarters · filed 2023-12-11 | $0.00 10-Q · filed 2023-12-11 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |